Daiichi Sankyo Company (4568-TO)

QUOTE AND NEWS
The Hindu Business Line  Jul 18  Comment 
Drug firm Alembic Pharmaceuticals today said it has received approval from the US health regulator for generic Olmesartan Medoxomil and Amlodipine tablets used for the treatment of hypertension. Th...
GenEng News  Jul 11  Comment 
Daiichi Sankyo has gained an option for exclusive rights to a cancer treatment to be discovered and developed at Max Planck Innovation’s Lead Discovery Center through a new collaboration built upon a discovery partnership launched by the pharma...
The Hindu Business Line  Jul 7  Comment 
Glenmark Pharmaceuticals has received final approval from the US health regulator for Amlodipine and Olmesartan Medoxomil tablets used in the treatment of hypertension. “Glenmark Pharmaceuticals In...
GenEng News  Jul 5  Comment 
Daiichi Sankyo said today it was ending its co-development in Japan with Coherus BioSciences of a biosimilar to Amgen’s marketed drug Enbrel ® (etanercept) for rheumatoid arthritis, ending a five-year-old partnership by the companies. The...
The Economic Times  Jul 4  Comment 
The court has not stopped the brothers from corporate transactions, provided they maintain the value of unpledged assets that could be considered to pay an arbitration award of over Rs 2,500 crore Daiichi won against them last year.
GenEng News  Jun 30  Comment 
Daiichi Sankyo reported mixed results from the Phase III NEUCOURSE and ALDAY clinical trials with its oral pain management candidate mirogabalin. The 14-week, placebo-controlled NEUCOURSE study in Asian patients with post-herpetic neuralgia met...
The Hindu Business Line  May 26  Comment 
Glenmark Pharmaceuticals today said it has received final approval from the US health regulator for its generic version Olmesartan Medoxomil tablets, used in the treatment of high blood pressure.
The Hindu Business Line  May 17  Comment 
Jubilant Life Sciences has received approval from the US health regulator to market amlodipine and olmesartan medoxomil tablets, used to treat hypertension, in the American market. Jubilant Pharma...





You may also be interested in articles related to Daiichi Sankyo Company (4568-TO):
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki